Stock AnalizSurgery Partners, Inc. SGRY
Hospital/Nursing Management · IPO 2015 · data as of November 13, 2026
Surgery Partners, Inc. (SGRY) is a healthcare company listed in the US with a market value of about $3.5B. In the twelve months to September 30, 2026 it had revenue of $3.4B and net income of -$87M, a net margin of -2.6%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (1/5).
Key numbers: a price to free cash flow of 17.4, 5-year revenue growth of 12% a year, a 5-year average ROIC of 5%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 89% below the current price.
Score: 1.4 / 5
Checks passed
- P/FCF below 20
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Interest covered more than 5 times
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4B | $3.3B | $3.1B | $2.7B | $2.5B | $2.2B | $1.9B | $1.8B | $1.8B | $1.1B | $960M |
| Net income | -$87M | -$78M | -$168M | -$12M | -$55M | -$71M | -$116M | -$75M | -$206M | $9M | $1M |
| Free cash flow | $203M | $196M | $210M | $205M | $78M | $30M | $204M | $56M | $105M | $86M | $51M |
| EPS (diluted) | $-0.67 | $-0.61 | $-1.33 | $-0.09 | $-0.59 | $-1.12 | $-3.19 | $-2.29 | $-4.96 | $0.20 | $0.04 |
| Net margin | -2.6% | -2.4% | -5.4% | -0.4% | -2.1% | -3.2% | -6.2% | -4.1% | -11.6% | 0.8% | 0.1% |
| ROIC | — | 5.4% | 5.0% | 5.1% | 5.5% | 5.5% | 4.4% | 5.8% | 2.2% | 10.7% | 9.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $24.40, 9% below the current price; targets range from $23.50 to $25.00; the consensus rating is “Hold”; expected EPS is $0.41 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Surgery Partners stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 89% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Surgery Partners pay a dividend?
Not currently.
Is Surgery Partners a good stock to buy?
We do not give buy or sell advice. Surgery Partners scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.